Stocktoria
DELCATH SYSTEMS, INC. DCTH
DELCATH SYSTEMS, INC. (DCTH) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $85.2M at a 3.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.69 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.878 |
| Retained earnings / assets | -4.278 |
| EBIT / assets | 0.005 |
| Equity / liabilities | 8.96 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| DCTH | DELCATH SYSTEMS, INC. | 6/9 | 1.26 | 165.4 | +129.1% |
| IRMD | IRADIMED CORP | 5/9 | 14.84 | 53.4 | +14.4% |
| TELA | TELA Bio, Inc. | 3/9 | -13.97 | — | +15.8% |
| LUNG | Pulmonx Corp | 3/9 | -11.04 | — | +8% |
| SGHT | Sight Sciences, Inc. | 5/9 | -5.95 | — | -3.1% |
| KMTS | KESTRA MEDICAL TECHNOLOGIES, LTD. | 5/9 | -0.94 | — | +59% |
| RCEL | AVITA Medical, Inc. | 3/9 | — | — | +11.5% |
About DELCATH SYSTEMS, INC.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
FAQ
Is DCTH financially healthy?
DELCATH SYSTEMS, INC.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does DCTH pay a dividend?
No, DELCATH SYSTEMS, INC. does not currently pay a dividend.
How profitable is DCTH?
In FY2025, DELCATH SYSTEMS, INC. had a net margin of 3.2% and a return on equity of 2.4%.
What is DCTH's P/E ratio?
DELCATH SYSTEMS, INC.'s trailing price-to-earnings (P/E) ratio is about 165.4×, based on its latest annual earnings.
What is the analyst price target for DCTH?
The average Wall-Street price target for DELCATH SYSTEMS, INC. is $21.35, about 24.8% above the recent price, from 5 analysts (consensus: strong buy).
Is DCTH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on DELCATH SYSTEMS, INC.: a Piotroski F-score of 6/9, an Altman Z″ in the grey zone, a P/E of about 165.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.